JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2026, 75(2):E2-E8 | DOI: 10.36290/csf.2026.023

Justification of a medicinal form development based on the api dimethylammonium 3-methyl-2-(2-((e)-styryl)quinazolin-4-ylthio)butanoate with hepatoprotective and antioxidant effects for the needs of military medicine

Antonina Avramenko1, Andrii Kaplaushenko1, Volodymyr Salionov2
1 Department of Physical, Colloidal, and Analytical Chemistry, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine
2 Department of Clinical Laboratory Diagnostics and Biochemistry, Zaporizhzhia State Medical and Pharmaceutical University, Ukraine

Objective: The study aims to substantiate the development of an oral dosage form for military medicine based on the API dimethylammonium 3-methyl-2-(2-((E)-styryl)quinazolin-4-ylthio)butanoate, which demonstrates antioxidant and hepatoprotective activity. The molecule’s physicochemical properties and dissociation constant were evaluated.

Materials and Methods: Computer modelling was used to assess lipophilicity, physicochemical parameters, and ADME characteristics via the SwissADME service. Drug-likeness was evaluated according to Lipinski’s Rule of Five. Conductometric studies of API solutions (0.0625–0.5 M) were performed with a Konduktometr N 5721 M to determine χ, λv, λ∞, α, and the dissociation constant (7.45 × 10-8–9.2 × 10-8). The ionization constant was used to calculate pK = 7.13, indicating the pH range of optimal absorption.

Results: ADME analysis showed high gastrointestinal absorption and suitable solubility, supporting the feasibility of an oral dosage form. Conductometric data confirmed the API to be a weak electrolyte with increasing dissociation at lower concentrations. The pK value suggests preferential absorption in the neutral to slightly alkaline environment of the small intestine. Considering its pharmacological activity, the API is promising for further development of tablets or capsules for military and clinical use.

Conclusions: The findings justify designing a gastro-resistant oral dosage form ensuring API stability in gastric acid and efficient intestinal absorption. Such a form is particularly valuable for military medicine due to its stability, portability, and suitability for emergency and rehabilitation settings.

Keywords: API, dimethylammonium 3-methyl-2-(2-((E)-styryl)quinozolin-4-ylthio)butanoate, conductometry, dissociation constant, ADME, antioxidant effect, hepatoprotective activity, oral medicinal form, military medicine

Accepted: May 27, 2026; Published: June 10, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Avramenko A, Kaplaushenko A, Salionov V. Justification of a medicinal form development based on the api dimethylammonium 3-methyl-2-(2-((e)-styryl)quinazolin-4-ylthio)butanoate with hepatoprotective and antioxidant effects for the needs of military medicine. Čes. slov. farm. 2026;75(2):E2-8. doi: 10.36290/csf.2026.023.
Download citation

References

  1. Radulescu D, et al. Oxidative stress in military missions - impact and management strategies: a narrative analysis. Life (Basel). 2024;14(5):567. doi:10.3390/life14050567. Go to original source... Go to PubMed...
  2. McElroy C, Day BJ. Antioxidants as potential medical countermeasures for chemical warfare agents and toxic industrial chemicals. Biochem Pharmacol. 2015;100:1-11. doi:10.1016/j.bcp.2015.10.003. Go to original source... Go to PubMed...
  3. Vargas-Mendoza N, et al. Hepatoprotective effect of silymarin. World J Hepatol. 2014;6(3):144-149. doi:10.4254/wjh.v6.i3.144. Go to original source...
  4. Khomenko I, et al. Hydrodynamic rupture of liver in combat patient: a case of successful application of "damage control" tactic in area of the hybrid war in East Ukraine. Surg Case Rep. 2017; 3:88. doi:10.1186/s40792-017-0363-6. Go to original source...
  5. Cobley JN, et al. Antioxidants as potential medical countermeasures for chemical warfare agents. Biochem Pharmacol. 2015;100:1-11. doi:10.1016/j.bcp.2015.10.003. Go to original source... Go to PubMed...
  6. Salama S, et al. Hepatoprotective potential of a novel quinazoline derivative in thioacetamide-induced liver toxicity. Front Pharmacol. 2022;13:943340. doi:10.3389/fphar.2022.943340 Go to original source... Go to PubMed...
  7. He F, et al. Quinazoline derivatives: synthesis and bioactivities. BMC Chem. 2013;7:95. doi:10.1186/1752-153X-7-95. Go to original source... Go to PubMed...
  8. Yang H, et al. A novel quinazoline derivative prevents and treats arsenic-induced liver injury by regulating the expression of RecQ family helicase. Int J Mol Sci. 2023;24(21):15521. doi:10.3390/ijms242115521. Go to original source...
  9. Al-Sayed E, et al. Antioxidant activity of novel quinazolinones bearing sulfonamide. Eur J Med Chem. 2020;197:111922. doi:10.1016/j.ejmech.2020.111922. Go to original source...
  10. Isaycheva KK, Kaplaushenko AG, Sameliuk YH, et al. Antioxidant agents in wartime: prospects for the development of new biologically active compounds based on 1,2,4-triazole derivatives. Ukr J Mil Med. 2025;2(6):125-133. doi:10.46847/ujmm.2025.2(6)-125. Go to original source...
  11. Dovbnya DV, Kaplaushenko AH, Frolova YuS, Pryglo ES. Synthesis and antioxidant properties of new (2,4- and 3,4-dimethoxyphenyl)-1,2,4-triazoles. Pharmacia. 2022;69(1):135-142. doi:10.3897/pharmacia.69.e74107. Go to original source...
  12. Muriel P. Role of free radicals in liver diseases. Hepatol Int. 2009;3(4):526-536. doi:10.1007/s12072-009-9158-6. Go to original source... Go to PubMed...
  13. Kunnumakkara AB, et al. Role of turmeric and curcumin in prevention and treatment of chronic diseases: lessons learned from clinical trials. ACS Pharmacol Transl Sci. 2023;6(4):447-518. doi:10.1021/acsptsci.2c00012. Go to original source... Go to PubMed...
  14. Khoroshun EM, et al. Peculiarities of severe liver gunshot wounds pathomorphosis. Svit Med Biol. 2025;2(92):197-201. doi:10.26724/2079-8334-2025-2-92-197-201. Go to original source...
  15. Lawry LL, et al. A qualitative assessment of disease and non-battle injuries in Ukraine since the Russian invasion. Confl Health. 2025;19:19. doi:10.1186/s13031-024-00632-2. Go to original source... Go to PubMed...
  16. Avramenko AI. Targeted search for hepatoprotectors with an antioxidant mechanism of action among 4-thioquinazoline derivatives based on structure-activity relationship patterns. PhD Thesis, Zaporizhzhia, 2011:239 p. http://dspace.zsmu.edu.ua/handle/123456789/25004.
  17. SwissADME. http://www.swissadme.ch/index.php.
  18. Skoryi M, Shcherbyna R, Kulish S, Salionov V, Cherchesova O. Výpočet ADME profilu a studie podobnosti s léčivy u nových derivátů 1,2,4-triazolu obsahujících radikál 2-brom-5-methoxyfenyl. Čes Slov Farm. 2025;74(3):E1-E5. doi:10.36290/csf.2025.024. Go to original source... Go to PubMed...
  19. Afzal AH, et al. Application of machine learning for the prediction of absorption, distribution, metabolism and excretion (ADME) properties from Cichorium intybus plant phytomolecules. Processes. 2024;12(11):2488. doi:10.3390/pr12112488. Go to original source...
  20. Roskoski R Jr. Rule of five violations among the FDA-approved small molecule protein kinase inhibitors. Pharmacol Res. 2023;191:106774. doi:10.1016/j.phrs.2023.106774. Go to original source... Go to PubMed...
  21. Muschong P, et al. Beyond the arbitrariness of drug-likeness rules. Electronics. 2024;13:9966. doi:10.3390/electronics14219966. Go to original source...
  22. Ganguly D, Samanta S. Effect of temperature on dissociation constant and determination of equivalent conductance at infinite dilution (Λ) of two weak acids. Explor Chem Complex. 2024;1:14. doi:10.31674/book.2024ecc.014. Go to original source...
  23. Li G, et al. Determination of the microscopic acid dissociation constant of PIP and its effect on antibiotic stability. Pharmacol Res. 2023;191:106500. doi:10.1016/j.phrs.2023.106500. Go to original source...




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.